Epigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets
AbstractThe development of cancer involves an immense number of factors at the molecular level. These factors are associated principally with alterations in the epigenetic mechanisms that regulate gene expression profiles. Studying the effects of chromatin structure alterations, which are caused by the addition/removal of functional groups to specific histone residues, are of great interest as a promising way to identify markers for cancer diagnosis, classify the disease and determine its prognosis, and these markers could be potential targets for the treatment of this disease in its different forms. This manuscript presents the current point of view regarding members of the recently described family of proteins that exhibit histone demethylase activity; histone demethylases are genetic regulators that play a fundamental role in both the activation and repression of genes and whose expression has been observed to increase in many types of cancer. Some fundamental aspects of their association with the development of cancer and their relevance as potential targets for the development of new therapeutic strategies at the epigenetic level are discussed in the following manuscript. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Lizcano, F.; Garcia, J. Epigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets. Pharmaceuticals 2012, 5, 963-990.
Lizcano F, Garcia J. Epigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets. Pharmaceuticals. 2012; 5(9):963-990.Chicago/Turabian Style
Lizcano, Fernando; Garcia, Jeison. 2012. "Epigenetic Control and Cancer: The Potential of Histone Demethylases as Therapeutic Targets." Pharmaceuticals 5, no. 9: 963-990.